Literature DB >> 17452183

Age-related macular degeneration in very old individuals with family history.

Asbjorg Geirsdottir1, Einar Stefansson, Fridbert Jonasson, Gudleif Helgadottir, Haraldur Sigurdsson.   

Abstract

PURPOSE: To study age-related macular degeneration (AMD) in old and very old individuals with family history of AMD to find the proportion of those with early and advanced AMD.
DESIGN: Retrospective cross-sectional cohort study of individuals with family history of AMD.
METHODS: Database of 897 AMD patients ages 75 to 102 years with family history of AMD was compiled. Color fundus photographs were graded in a masked fashion according to the International Classification of AMD.
RESULTS: With increasing age, a gradually larger proportion of participants had advanced AMD; 54% (469 of 863) of all those 75 years and older had advanced AMD, 64% (258 of 406) of all those 85 years and older, 74% (37 of 50) of all those 95 years and older, and all (eight of eight) 100 years and older had advanced AMD.
CONCLUSIONS: All the centenarians in the present study had advanced AMD.

Entities:  

Mesh:

Year:  2006        PMID: 17452183     DOI: 10.1016/j.ajo.2006.11.057

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  CX3CR1 polymorphisms and the risk of age-related macular degeneration.

Authors:  Baofeng Ma; Guangfu Dang; Shaoyuan Yang; Lian Duan; Yanwei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  An association between polymorphism of the heme oxygenase-1 and -2 genes and age-related macular degeneration.

Authors:  Ewelina Synowiec; Jerzy Szaflik; Marta Chmielewska; Katarzyna Wozniak; Anna Sklodowska; Maja Waszczyk; Mariola Dorecka; Janusz Blasiak; Jacek Pawel Szaflik
Journal:  Mol Biol Rep       Date:  2011-06-07       Impact factor: 2.316

3.  Genetic polymorphism of the iron-regulatory protein-1 and -2 genes in age-related macular degeneration.

Authors:  Ewelina Synowiec; Magdalena Pogorzelska; Janusz Blasiak; Jerzy Szaflik; Jacek Pawel Szaflik
Journal:  Mol Biol Rep       Date:  2012-02-14       Impact factor: 2.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.